###begin article-title 0
###xml 49 54 49 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 40 45 <span type="species:ncbi:9606">human</span>
A single-nucleotide polymorphism in the human p27kip1 gene (-838C>A) affects basal promoter activity and the risk of myocardial infarction
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 175 180 175 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 360 365 360 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 424 429 424 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 581 586 581 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 463 467 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Excessive proliferation of vascular smooth muscle cells and leukocytes within the artery wall is a major event in the development of atherosclerosis. The growth suppressor p27kip1 associates with several cyclin-dependent kinase/cyclin complexes, thereby abrogating their capacity to induce progression through the cell cycle. Recent studies have implicated p27kip1 in the control of neointimal hyperplasia. For instance, p27kip1 ablation in apolipoprotein-E-null mice enhanced arterial cell proliferation and accelerated atherogenesis induced by dietary cholesterol. Therefore, p27kip1 is a candidate gene to modify the risk of developing atherosclerosis and associated ischaemic events (i.e., myocardial infarction and stroke).
###end p 2
###begin title 3
Results
###end title 3
###begin p 4
###xml 84 89 84 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 395 400 395 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 579 581 579 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 386 391 <span type="species:ncbi:9606">human</span>
In this study we found three common single-nucleotide polymorphisms in the human p27kip1 gene (+326T>G [V109G], -79C>T, and -838C>A). The frequency of -838A carriers was significantly increased in myocardial infarction patients compared to healthy controls (odds ratio [OR] = 1.73, 95% confidence interval [95%CI] = 1.12-2.70). In addition, luciferase reporter constructs driven by the human p27kip1 gene promoter containing A at position -838 had decreased basal transcriptional activity when transiently transfected in Jurkat cells, compared with constructs bearing C in -838 (P = 0.04).
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 60 65 60 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
These data suggest that -838A is associated with reduced p27kip1 promoter activity and increased risk of myocardial infarction.
###end p 6
###begin title 7
Background
###end title 7
###begin p 8
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 651 655 651 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink">cip1</sup>
###xml 660 664 660 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 673 677 673 677 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip2</sup>
###xml 699 704 699 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ink4a</sup>
###xml 709 714 709 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ink4b</sup>
###xml 719 724 719 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ink4c</sup>
###xml 729 734 729 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ink4d</sup>
###xml 737 738 737 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
The proliferation of leukocytes and vascular smooth muscle cells (VSMCs) within the artery wall is a hallmark of the atherosclerotic process [1]. The exposure of coronary arteries to chemical and mechanical injury triggers an inflammatory response characterized by excessive arterial cell proliferation. Progression through the cell cycle depends on the sequential activation of several cyclin-dependent kinases (CDKs). Activation of CDKs requires their interaction with regulatory subunits named cyclins. In resting cells, cyclin-CDK complexes are inhibited by the reversible association with CDK inhibitory proteins (CKIs) of the Cip/Kip family (p21cip1, p27kip1, and p57kip2) and Ink4 family (p16Ink4a, p15Ink4b, p18Ink4c, p19Ink4d) [2].
###end p 8
###begin p 9
###xml 57 62 57 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 179 180 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 198 203 198 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 338 343 338 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 457 458 457 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 556 561 556 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 682 687 682 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 781 785 781 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 912 914 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 996 1001 996 1001 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 284 289 <span type="species:ncbi:9606">human</span>
###xml 502 506 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 659 663 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 768 772 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 1116 1122 <span type="species:ncbi:9606">humans</span>
In recent years, accumulating evidence has implicated p27kip1 as an important endogenous regulator of leukocyte and VSMC proliferation in various pathophysiological situations [3-7]. Remarkably, p27kip1 expression and proliferation of VSMCs and leukocytes are inversely correlated in human atheroma, and a significantly lower level of p27kip1 expression has been reported in primary atherosclerotic and restenotic tissue versus nondiseased arterial tissue [8-10]. We have previously shown that fat-fed mice deficient in both apolipoprotein E (apoE) and p27kip1 display increased arterial cell proliferation and accelerated atherogenesis compared to apoE-null mice with an intact p27kip1 gene [11]. We also found that reconstitution of sublethally irradiated apoE-null mice with p27kip1-deficient bone marrow was sufficient to enhance arterial macrophage proliferation and atherosclerosis induced by fat feeding [12]. In view of these findings, the present study was designed to assess whether p27kip1 is a candidate gene to modify the risk of developing atherosclerosis and consecutive myocardial infarction (MI) in humans.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
###xml 21 26 21 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Identification of p27kip1 polymorphisms and genotyping of MI patients and controls
###end title 11
###begin p 12
###xml 95 100 95 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 280 285 280 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 473 478 473 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 978 982 978 982 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip </sup>
###xml 1023 1027 1023 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink">jab1</sup>
###xml 1076 1081 1076 1081 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 1094 1096 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1190 1195 1190 1195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 1244 1249 1244 1249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 1255 1257 1255 1257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 86 91 <span type="species:ncbi:9606">human</span>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 464 469 <span type="species:ncbi:9606">human</span>
The complete coding sequence as well as 1500 base pairs of the promoter region of the human p27kip1 gene were analysed through single-strand conformation analysis (SSCA) in 50 MI patients and 50 controls. As shown in Fig. 1, we identified different electrophoretic patterns in p27kip1 DNA fragments obtained with primers P3-F+P3-R3, P1-F+P1-R, and E1-F+E1-R (Table 1). After direct sequencing, we identified three single-nucleotide polymorphisms (SNPs) within the human p27kip1 gene: +326T>G (V109G), -79C>T, and -838C>A (nucleotide positions numbered relative to the start of transcription according to Genbank accession number AB003688). +326T>G (V109G) and -79C>T have been previously described (rs2066827 and rs34330, respectively), and -838C>A is a novel polymorphism. +326T>G (V109G) is a missense polymorphism in exon 1 which has been previously analysed in the context of susceptibility to several types of cancer [13-15]. This polymorphism lies within the domain of p27kip that is required for interaction with p38jab1, a protein-protein association that promotes p27kip1 proteolysis [16]. The -79C>T is a polymorphism within a U-rich element in the 5' untranslated sequence of p27kip1 which is necessary for the translation of the p27kip1 mRNA [17].
###end p 12
###begin p 13
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 533 535 533 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 704 706 704 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 288 296 <span type="species:ncbi:9606">patients</span>
To genotype these polymorphisms in MI patients and controls, we developed a protocol based on endonuclease digestion of DNA fragments obtained by amplification with the primers shown in Table 2. Table 3 summarizes the genotype and allele frequencies for the three polymorphisms in 180 MI patients and 250 controls. The frequencies for the -79C>T and +326T>G (V109G) polymorphisms did not differ between the two groups. For the -838C>A polymorphism, the A allele was significantly more frequent in cases compared to control subjects (P = 0.002; OR = 1.53; 95%CI = 1.15-2.03). Carriers of the A allele (AA+AC genotypes) would have an almost twofold risk of suffering an episode of MI compared to controls (P = 0.009; OR = 1.73; 95%CI = 1.12-2.70).
###end p 13
###begin title 14
###xml 85 90 85 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 76 81 <span type="species:ncbi:9606">human</span>
Functional effect of the -838C>A polymorphism in the promoter region of the human p27kip1 gene
###end title 14
###begin p 15
###xml 52 57 52 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 336 341 336 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 444 449 444 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 494 498 494 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 498 500 498 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 512 516 512 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 516 517 516 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink">C</sub>
###xml 875 879 875 879 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 879 881 879 881 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 915 919 915 919 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 919 921 919 921 <sub xmlns:xlink="http://www.w3.org/1999/xlink">C </sub>
###xml 922 924 922 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 938 939 938 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 327 332 <span type="species:ncbi:9606">human</span>
Having demonstrated that the -838A allele of the p27kip1 gene is associated with MI, we sought to determine whether the -838C>A genetic variation has functional consequences. Because this SNP lies within the promoter region, we examined in transiently transfected Jurkat cells the activity of reporter constructs driven by the human p27kip1 gene promoter containing either nucleotide A or C at position -838. We generated two different pGL3-p27kip1 constructs for each A and C alleles (pGL3-p27kip1A and pGL3-p27kip1C, respectively), and performed three independent transfections with each construct. To correct for differences in transfection efficiency, cells were cotransfected with a plasmid encoding for the green fluorescent protein (GFP) (see Methods). After normalizing luciferase activity by the internal GFP control, the average transcriptional activity of pGL3-p27kip1A was 34% less than that of pGL3-p27kip1C (P = 0.04) (Fig. 2).
###end p 15
###begin title 16
Discussion
###end title 16
###begin p 17
###xml 187 192 187 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 346 351 346 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 478 483 478 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 500 505 500 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 708 713 708 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 814 815 814 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 639 643 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 788 793 <span type="species:ncbi:9606">human</span>
VSMC and macrophage proliferation within the artery wall is a major event in the development of the atherosclerotic lesion, a pathological hallmark of coronary artery disease. The CKI p27kip1 is a tumour suppressor that functions as a brake against excessive cell proliferation [2]. Several recent studies have suggested an important role for p27kip1 as a negative regulator of arterial cell proliferation and atheroma development. First, both whole body genetic ablation of p27kip1 and selective p27kip1 inactivation in haematopoietic precursors increase neointimal cell proliferation and accelerates atherosclerosis in fat-fed apoE-null mice [11,12]. Second, evidence has been presented suggesting that p27kip1 expression and arterial cell proliferation are inversely correlated within human neointimal lesions [8-10].
###end p 17
###begin p 18
###xml 811 816 811 816 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
In addition to environmental risk factors, such as smoking, hypertension, and hypercholesterolaemia, genetic factors may also increase the risk of atherosclerosis and associated ischaemic events. For example, evidence exists indicating that polymorphisms in the components of the renin-angiotensin system, nitric oxide synthases, apolipoproteins, and several cytokines/chemokines and growth factors could modulate the risk of suffering an episode of MI. Genetic variations must fulfil two criteria to be considered candidate modifiers of cardiovascular risk: the corresponding gene encodes a protein involved in vascular physiology or in atheroma development, and the nucleotide change affects gene expression and/or function. In the present study, we have investigated whether genetic variations within the p27kip1 are associated with increased risk of MI. Among the three SNPs described here, only -838C>A showed differences in allele frequency between cases and controls. Carriers of the -838A allele (AA+AC genotypes) would have an almost twofold risk of suffering an episode of MI compared to controls (OR = 1.73; 95%CI = 1.12-2.70), and the risk increased to twofold for AA homozygous (OR = 2.27; 95%CI = 1.26-4.10; AA versus CC).
###end p 18
###begin p 19
###xml 54 58 54 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 100 105 100 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 262 267 262 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 520 525 520 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 1043 1048 1043 1048 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 1103 1105 1103 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1106 1108 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1089 1094 <span type="species:ncbi:9606">human</span>
Because -838C>A lies within the promoter region of p27kip1, we examined whether this SNP affects p27kip1 gene expression. Transient transfection experiments revealed a 34% reduction in promoter activity for -838A compared with the -838C allele. Thus, reduced p27kip1 expression in -838A carriers might facilitate neointimal hyperplasia and therefore accelerate atheroma progression and increase the risk of MI. Distinct transcription factor binding and/or activity may contribute to the difference in -838A and -838C p27kip1 promoter activity. Indeed, analysis of the promoter sequence containing the -838C>A SNP using the MatInspector v2.2 and TRANSFAC v7.3 software revealed potential binding sites for several transcription factors, including STAT and IK-2. However, additional studies are required to conclusively address whether specific transcription factors are involved in different transcriptional activation of -838A versus -838C. These studies should provide valuable insight not only for atherosclerosis but also for cancer, as p27kip1 expression appears to be altered in some human tumors [18,19].
###end p 19
###begin p 20
###xml 31 36 31 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 201 206 201 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 437 442 437 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
The use of SSCA to identify p27kip1 SNPs may be a limitation of our study, because this technique apparently fails to identify approximately 20% of SNPs. Therefore, additional functionally relevant p27kip1 SNPs may exist. We also recognize that the number of cases analysed in our study is limited. This was mostly because we included only patients with angiographically diseased vessels, a strategy that was deemed important because p27kip1 has been involved in the control of neointimal thickening [8-12]. The possibility of false-positive results due to population stratification must be considered in association studies, but this is unlikely to occur in our study because we analysed individuals from a homogeneous white population. In addition, genotype frequencies were in the Hardy-Weinberg equilibrium in both groups, suggesting that the observed frequencies are representative of cases and controls.
###end p 20
###begin title 21
Conclusions
###end title 21
###begin p 22
###xml 36 41 36 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 308 312 308 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 363 368 363 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 209 217 <span type="species:ncbi:9606">patients</span>
Three polymorphisms of the human p27kip1 gene (-838C>A, -79C>T, and V109G) were analysed as candidates to modify the risk of suffering MI. We found a significantly higher frequency of the -838A carriers in MI patients compared to controls. Importantly, this polymorphism was associated with reduced basal p27kip1gene promoter activity. We suggest that reduced p27kip1 expression in -838A carriers may facilitate the proliferative response associated with atherosclerosis, thus increasing the risk of MI in these individuals.
###end p 22
###begin title 23
Methods
###end title 23
###begin title 24
Subjects
###end title 24
###begin p 25
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 322 330 <span type="species:ncbi:9606">patients</span>
A total of 180 patients who had suffered an episode of MI were included in the present study. All patients were male, no more than 55 years of age, and had at least one angiographically diseased vessel (a vessel was considered diseased when the angiography showed a narrowing of at least 70% in the lumen diameter). These patients were recruited for a search of genetic factors involved in MI [20].
###end p 25
###begin p 26
###xml 306 314 <span type="species:ncbi:9606">Patients</span>
The control group consisted of 250 healthy males younger than 55 years (blood bank donors and Hospital Universitario Central de Asturias staff). Although control subjects did not have a history of cardiovascular disease, they were not angiographically analysed to exclude the presence of diseased vessels. Patients and controls were white and were all from the same region (Asturias, northern Spain, 1 million total population) and gave their informed consent to participate in the study, which was approved by the Ethical Committee of the Hospital Universitario Central de Asturias.
###end p 26
###begin title 27
###xml 58 63 58 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 49 54 <span type="species:ncbi:9606">human</span>
Identification and genotyping of SNPs within the human p27kip1 gene
###end title 27
###begin p 28
###xml 90 95 90 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 167 172 167 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 373 378 373 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
Genomic DNA was obtained from each individual included in the study. In the search for p27kip1 SNPs, we analysed 50 patients and 50 controls using SSCA. The entire p27kip1 coding sequence and 1500 nucleotides of the promoter region were amplified in overlapping fragments of 300-450 base pairs by PCR (Table 1 shows the sequences of the PCR primers; the sequence of the p27kip1 gene was obtained from , accession number NT009714). SSCA analysis was performed as previously described [21]. The DNA from samples showing atypical electrophoretic patterns was amplified, purified, and sequenced using an automated ABI310 system.
###end p 28
###begin p 29
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
For genotyping of the three SNPs in patients and controls, genomic DNA was amplified by PCR to generate DNA fragments containing the SNP, and these fragments were digested with restriction enzymes that produced distinct patterns of digestion depending on the allele present (primers and restriction enzymes are listed in Table 2). The digested fragments were electrophoresed on 3% agarose gels, and the pattern corresponding to each individual was visualized after ethidium bromide staining of the gel.
###end p 29
###begin title 30
###xml 19 24 19 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
Construction of p27kip1 reporter vectors
###end title 30
###begin p 31
###xml 52 56 52 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 217 223 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GGTACC</italic>
###xml 263 269 263 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AAGCTT</italic>
###xml 308 311 308 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 317 320 317 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hin</italic>
###xml 451 455 451 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 455 457 455 457 <sub xmlns:xlink="http://www.w3.org/1999/xlink">C </sub>
###xml 477 481 477 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 481 483 481 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
DNA fragments from the 5' flanking region of the p27kip1gene between nucleotides - 1100 to -27, containing either C or A at -838, were generated through PCR of two CC and AA homozygous individuals with forward (TATGATGGTACCAGACGTTCGCTTTGGCTTC) and reverse (GCACGAAAGCTTCTCTCGCACTCTCAAAAA) primers containing KpnI and HindIII sites, respectively. The PCR products were cloned into the pGL3-Basic plasmid (Promega, Madison, WI, USA) to generate pGL3-p27kip1C (-838C) and pGL3-p27kip1A (-838A). For each genotype, two plasmids were generated and confirmed by direct sequencing.
###end p 31
###begin title 32
Cell culture and luciferase reporter gene assays
###end title 32
###begin p 33
###xml 98 99 92 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 105 107 99 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 589 593 581 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 593 595 585 587 <sub xmlns:xlink="http://www.w3.org/1999/xlink">C </sub>
###xml 609 613 601 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 613 614 605 606 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 880 881 871 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 231 235 <span type="species:ncbi:9913">calf</span>
Jurkat cells (American Type Culture Collection) were incubated at 37degreesC in a humidified 5% CO2-95% O2 atmosphere in RPMI medium supplemented with 100U/ml penicillin, 0.1 mg/ml streptomycin, 2 mmol/l L-glutamine, and 10% fetal calf serum. Transfections were performed with SuperFect Transfection Reagent following the manufacturer's protocol (Quiagen, Valencia, CA, USA). In a blinded manner, the promoter/luciferase reporter gene (2 mug) was cotransfected with 1 mug of pEGFP-N1 control vector. Three independent transfections were done for each of the four reporter genes (2 pGL3-p27kip1C and 2 pGL3-p27kip1A, a total of six transfections for each SNP). For luciferase activity assay, cells were collected by centrifugation, washed twice with PBS, and lysed with 100 mul of cell lysis reagent (Promega). Insoluble protein was removed by a 10-minute centrifugation at 15,000 g, and the supernatants were immediately assayed for luciferase activity and green fluorescence. Luciferase assays were performed using a Victor 4120 multilabel counter (Perkin Elmer, Boston, MA, USA) and the Promega luciferase assay kit. Cell extract (50 mul) and 100 mul of luciferin mixture were incubated for 5 s and light output was monitored for 5 s. For each sample, arbitrary light units from luciferase were normalized versus the measure of green fluorescence.
###end p 33
###begin title 34
Statistical analysis
###end title 34
###begin p 35
###xml 617 618 617 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Allele and genotype frequencies in patients and controls were compared using a chi-square test. This test was also used to determine if the observed genotype frequencies in cases and controls differed from those expected under the Hardy-Weinberg equilibrium. Multivariate analysis was used to compare the genotype and allele frequencies between the groups according to the presence/absence of classical risk factors. Odds ratios (OR) with 95% confidence intervals (CI) were obtained to calculate the relative risk of MI associated with the genotypes. The results of transfections were analysed by two-tailed unpaired t-test. All statistical analyses were performed with the SPSS statistical package (v.11.0).
###end p 35
###begin title 36
Authors' contributions
###end title 36
###begin p 37
###xml 155 160 155 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 284 288 284 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1</sup>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
JRR and AB recruited the patients and controls and performed all the clinical analysis. PG, EC, and VAlvarez performed the genetic analysis (search for p27kip1 polymorphisms and genotyping) and the statistical analysis. AD-J, VAndres, and PG designed and performed the analysis of p27kip1-promoter polymorphisms with reporter vectors. All the authors read and approved the final version of the manuscript.
###end p 37
###begin title 38
Acknowledgements
###end title 38
###begin p 39
###xml 253 260 <span type="species:ncbi:113210">Manzano</span>
PG was the recipient of a fellowship from the Fundacion para el Fomento en Asturias de la Investigacion Cientifica Aplicada y Tecnologica (FICYT, BP 01-082). AD-J received salary support from Fondo Social Europeo (CSIC-Programa I3P). We thank MJ Andres-Manzano for preparing the figures. This work was supported by grants from the Spanish Fondo de Investigaciones Sanitarias to EC (FIS 03/05) and from the Spanish Ministry of Science and Technology and Fondo Europeo de Desarrollo Regional to VAndres (SAF2002-1443).
###end p 39
###begin article-title 40
Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies
###end article-title 40
###begin article-title 41
Inhibitors of mammalian G1 cyclin-dependent kinases
###end article-title 41
###begin article-title 42
###xml 33 38 33 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
Role of the growth suppressor p27kip1 during vascular remodeling
###end article-title 42
###begin article-title 43
Interleukin-1beta inhibits expression of p21(WAF1/CIP1) and p27(KIP1) and enhances proliferation in response to platelet-derived growth factor-BB in smooth muscle cells
###end article-title 43
###begin article-title 44
###xml 20 25 20 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
Mechanosensitive p27kip1 regulation and cell cycle entry in vascular smooth muscle cells
###end article-title 44
###begin article-title 45
###xml 51 56 <span type="species:ncbi:9606">human</span>
Aortic endothelial cells regulate proliferation of human monocytes in vitro via a mechanism synergistic with macrophage colony-stimulating factor
###end article-title 45
###begin article-title 46
###xml 3 8 3 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
p27kip1 regulates T cell proliferation
###end article-title 46
###begin article-title 47
Expression of cyclin-dependent kinase inhibitors in vascular disease
###end article-title 47
###begin article-title 48
###xml 48 53 48 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 60 65 60 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">cip1 </sup>
###xml 68 73 <span type="species:ncbi:9606">human</span>
Quantification of the cell-cyclin inhibitors p27kip1 and p21cip1 in human atherectomy specimens: primary stenosis versus restenosis
###end article-title 48
###begin article-title 49
###xml 118 123 <span type="species:ncbi:9606">human</span>
Concordant upregulation of type II-TGF-beta-receptor, the cyclin-dependent kinases inhibitor p27/Kip1 and cyclin E in human atherosclerotic tissue: implications for lesion cellularity
###end article-title 49
###begin article-title 50
###xml 25 30 25 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
The growth suppressor p27kip1 protects against diet-induced atherosclerosis
###end article-title 50
###begin article-title 51
###xml 29 34 29 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
Selective inactivation of p27kip1 in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis
###end article-title 51
###begin article-title 52
CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma
###end article-title 52
###begin article-title 53
Mutational analysis of the p27(kip1) gene in hepatocellular carcinoma
###end article-title 53
###begin article-title 54
Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors
###end article-title 54
###begin article-title 55
###xml 56 61 56 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
Degradation of the cyclin-dependent-kinase inhibitor p27kip1 is instigated by jab1
###end article-title 55
###begin article-title 56
A U-rich element in the 5' untranslated region is necessary for the translation of p27 mRNA
###end article-title 56
###begin article-title 57
###xml 15 20 15 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
The role of p27kip1 in proteasome inhibitor induced apoptosis
###end article-title 57
###begin article-title 58
Multiple functions of p27Kip1 and its alterations in tumor cells: a review
###end article-title 58
###begin article-title 59
Genetic variation at the chemokines receptors CCR5/CCR2 in myocardial infarction
###end article-title 59
###begin article-title 60
###xml 145 153 <span type="species:ncbi:9606">patients</span>
Hypertrophic cardiomyopathy: low frequency of mutations in the beta myosin heavy chain (MYH7) and cardiac troponin T (TNNT2) genes among Spanish patients
###end article-title 60
###begin title 61
Figures and Tables
###end title 61
###begin p 62
###xml 84 89 84 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Single-strand conformation analysis of the -838C&gt;A polymorphism within the human p27<sup>kip1 </sup>gene</bold>
###xml 75 80 <span type="species:ncbi:9606">human</span>
Single-strand conformation analysis of the -838C>A polymorphism within the human p27kip1 gene. Note the distinct electrophoretic patterns for AA homozygotes, CC homozygotes, and CA heterozygotes.
###end p 62
###begin p 63
###xml 111 116 111 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
###xml 0 172 0 172 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Transcriptional activity in Jurkat cells transfected with luciferase reporter gene constructs driven by the p27<sup>kip1 </sup>gene promoter containing the -838C or A allelic variants</bold>
###xml 326 328 324 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 338 339 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Transcriptional activity in Jurkat cells transfected with luciferase reporter gene constructs driven by the p27kip1 gene promoter containing the -838C or A allelic variants. Luciferase activity was normalized by the internal control green fluorescent protein. Data represent the means +/- SD of six independent transfections (P = 0.04 in t-test).
###end p 63
###begin p 64
###xml 31 36 31 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
Primers used to amplify the p27kip1 gene for single-strand conformation analysis (SSCA).
###end p 64
###begin p 65
* F: forward; R, reverse.
###end p 65
###begin p 66
Primers used to genotype the single-nucleotide polymorphisms (SNPs).
###end p 66
###begin p 67
###xml 52 55 52 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
* F: forward; R, reverse. ** A mismatch to create a TaqI site when -838C is present is shown in lower case.
###end p 67
###begin p 68
###xml 59 64 59 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">kip1 </sup>
Genotype frequencies for the -838C>A, -79C>T, and V109G p27kip1 single-nucleotide polymorphisms (SNPs).
###end p 68
###begin p 69
###xml 1 3 1 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
*P = 0.009; OR = 1.73, 95%CI = 1.12-2.70 (AA+AC) vs CC. For each SNP, the table shows the total number of cases for each genotype and their relative frequencies among controls and patients with myocardial infarction.
###end p 69

